

Enrollment Letter in ATDC - Aurobindo Pharma Ltd.

1 message

Rakesh Maganti <Rakesh.Maganti@aurobindo.com>
To: wamanrasve987@gmail.com <wamanrasve987@gmail.com>
Cc: Santhi Kiran Kurra <SanthiKiran.Kurra@aurobindo.com>

Thu, 2 Dec, 2021 at 9:56 am

Dear Waman,

Congratulations!!!

We are pleased to inform you, that you have been selected in the **Technical and HR Interview** conducted for the enrollment process in the structured training program sponsored by Aurobindo Pharma Ltd at their Aurobindo Training & Development Centre (ATDC) for a period of 4 months along with a stipend of Rs. 7,000/- per month.

Your date of reporting is scheduled on **06th December 2021** at ATDC- APLRC- II. (Address: Isnapur, Indrakaran Village, Sangareddy Dist. Hyderabad-Attached the route map)

You are hereby informed to submit the below documents on the date of reporting.

- 1. S.S.C (Original)
- 2. Secondary Higher Qualification (Original)
- 3. Higher Education Qualification (Original)
- 4. 3 passport size photos
- 5. Photocopies of Aadhar card, Voter ID, Pan Card (please carry originals too for verification)
- 6.Physical fitness certificate from registered doctor. (Attached the document)
- 7.Covid -19 Negative report(RTPCR).
- 8. Covid Vaccine certificates (1st & 2nd Doses)
- 9. Copy of this mail

Please make a note on the below:

- The offer is valid only if you are qualified in MSc examinations and it stands cancelled automatically, in case of any backlogs.
- In case if you fail to turn up on 06th December, it is presumed that you have no interest to enroll in this training program and opportunity will be given to other candidates.
- Candidates are requested to take care of their boarding and lodging (accommodation) on their own cost. However, bus facility is being provided by the organization.

We are looking forward for your joining and please acknowledge to this mail with your acceptance to the offer.

<u>About us</u>: Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

Aurobindo Europe represents a significant segment within the Group's global presence. Aurobindo is committed to grow its operations in Europe considering the importance of the generic market. Since launching its European commercial operations in 2006 with the acquisition of Mil pharm in the UK and Pharmacin in the Netherlands in 2007, Aurobindo has further expanded its footprint in continental Europe by commencing operations in several territories including (but not limited to) Italy, Spain, Portugal, Romania, Malta and Germany. Aurobindo's state of the art EU release lab and captive warehouse in Malta serves as a logistics center for its European operations.

Thanks & Regards,

Rakesh Maganti

Deputy Manager - Human Resources,

Aurobindo Pharma Ltd

APL Research Centre-I,

Sy. No. 313, Qutubullapur, Bachupally,

Hyderabad, Telangana - 500 090

Cell: 9703344199, Extn:1345



DISCLAIMER:

All information and attachments included in this email are confidential and intended for the original recipient only. It is strictly forbidden to share any part of this message with any third party. If you received this message by mistake, please reply to this message and follow with its deletion, so that we can ensure such a mistake does not occur in the future.

Aurobindo Pharma Ltd and its subsidiaries are GDPR-compliant. If you have any questions related to GDPR compliance OR data protection - please contact our **Data Protection Officer**. To learn more about how we comply with GDPR and, as a result, care for the security and privacy of personal data we collected from you, visit **this page**.